EA202090898A1 - ANTITRANSTYRETIN ANTIBODIES - Google Patents

ANTITRANSTYRETIN ANTIBODIES

Info

Publication number
EA202090898A1
EA202090898A1 EA202090898A EA202090898A EA202090898A1 EA 202090898 A1 EA202090898 A1 EA 202090898A1 EA 202090898 A EA202090898 A EA 202090898A EA 202090898 A EA202090898 A EA 202090898A EA 202090898 A1 EA202090898 A1 EA 202090898A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ttp
antibodies
antitranstyretin
amyloidosis
accumulation
Prior art date
Application number
EA202090898A
Other languages
Russian (ru)
Inventor
Джошуа Реджинальд Солменс
Светлана Александер
Робин Барбур
Джеффри Н. Хигаки
Тарлохан С. Ниджджар
Original Assignee
Протена Биосайенсис Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Протена Биосайенсис Лимитед filed Critical Протена Биосайенсис Лимитед
Priority claimed from PCT/US2018/054720 external-priority patent/WO2019071205A1/en
Publication of EA202090898A1 publication Critical patent/EA202090898A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Данное изобретение обеспечивает антитела, которые специфически связываются с транстиретином (ТТР). Указанные антитела могут быть использованы для лечения или осуществления профилактики заболеваний или нарушений, связанных с накоплением ТТР или накоплением отложений ТТР (например, амилоидоза ТТР). Указанные антитела также могут быть использованы для диагностики амилоидоза ТТР, ингибирования или уменьшения агрегации ТТР и для мониторинга эффективности терапий ТТР, среди других применений.This invention provides antibodies that specifically bind to transthyretin (TTP). These antibodies can be used to treat or prevent diseases or disorders associated with the accumulation of TTP or the accumulation of TTP deposits (eg, TTP amyloidosis). These antibodies can also be used to diagnose TTP amyloidosis, inhibit or reduce TTP aggregation, and to monitor the effectiveness of TTP therapies, among other uses.

EA202090898A 2017-12-14 2018-10-05 ANTITRANSTYRETIN ANTIBODIES EA202090898A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762598965P 2017-12-14 2017-12-14
PCT/US2018/054720 WO2019071205A1 (en) 2017-10-06 2018-10-05 Anti-transthyretin antibodies

Publications (1)

Publication Number Publication Date
EA202090898A1 true EA202090898A1 (en) 2020-07-06

Family

ID=71833559

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090898A EA202090898A1 (en) 2017-12-14 2018-10-05 ANTITRANSTYRETIN ANTIBODIES

Country Status (1)

Country Link
EA (1) EA202090898A1 (en)

Similar Documents

Publication Publication Date Title
EA201791712A1 (en) ANTIBODIES TO TRANSTIRETIN
EA201791711A1 (en) ANTIBODIES TO TRANSTIRETIN
EA201791710A1 (en) ANTIBODIES TO TRANSTIRETIN
MX2020003041A (en) Anti-transthyretin antibodies.
EA201990594A1 (en) ANTI-TIM-3 ANTIBODIES AND THEIR APPLICATION
EA201790834A1 (en) ANTIBODY MOLECULES TO PD-L1 AND THEIR APPLICATION
EA201691765A1 (en) ANTIBODY MOLECULES AGAINST LAG-3 AND THEIR APPLICATIONS
EA202190377A9 (en) CXCR4 INHIBITOR COMPOSITIONS AND METHODS FOR PREPARATION AND APPLICATION
WO2018007924A3 (en) Anti-transthyretin antibodies
EA201891539A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
WO2018007923A3 (en) Anti-transthyretin antibodies
EA201792604A1 (en) AUTOTAXIN INHIBITORS AND THEIR APPLICATIONS
WO2018007922A3 (en) Anti-transthyretin antibodies
PH12020550141A1 (en) Antibody molecules to cd138 and uses thereof
EA201991464A1 (en) ANTIBODY TO α-SINUCLEIN AND ITS APPLICATION
EA201991726A1 (en) HUMANIZED ANTIBODY FOR TREATMENT OR PREVENTION OF COGNITIVE DISORDERS, METHOD OF ITS OBTAINING AND AN AGENT FOR TREATMENT OR PREVENTION OF COGNITIVE DISORDERS WITH ITS APPLICATION
MX2021016098A (en) Humanized antibody molecules to cd138 and uses thereof.
EA202092225A1 (en) CONNECTIONS AND THEIR APPLICATION
EA202191058A1 (en) ANTIBODIES AGAINST MUCIN-16 AND METHODS OF THEIR APPLICATION
EA202090898A1 (en) ANTITRANSTYRETIN ANTIBODIES
EA202090891A1 (en) ANTIBODY MOLECULES AGAINST CD138 AND THEIR APPLICATION
EA201891445A1 (en) ANTIBODY MOLECULES THAT BIND WITH TNF-ALPHA
EA201891895A1 (en) INHIBITORS OF β-ARRESTINE INTERACTIONS WITH NEUROKININ 1 RECEPTOR FOR THE TREATMENT OF PAIN
AR113345A1 (en) ANTI-TRANSTIRETIN ANTIBODIES
MY193688A (en) Anti-transthyretin antibodies